| Autor: |
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Hepatology Communications, Vol 4, Iss 6, Pp 904-915 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2471-254X |
| DOI: |
10.1002/hep4.1496 |
| Popis: |
Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community. The prevalence and range of posttreatment resistance‐associated substitutions (RASs) was determined in Australian patients with open access to DAAs through a wide range of prescribers. NS3, NS5A, and NS5B regions were amplified by polymerase chain reaction and analyzed by population sequencing. Clinically relevant RASs were identified using online databases (ReCALL and Geno2Pheno[hcv]). Of 572 samples, 60% were from genotype 3 and 27% from genotype 1a. Ninety‐two percent of people failed a DAA regimen containing an NS5A inhibitor, including 10% with a pangenotype regimen. NS5A RASs were detected in 72% of people with genotype 1 and 80% with genotype 3. For genotype 1, there was a range of RASs across the NS5A region, while for genotype 3, the Y93H RAS predominated (72%). The prevalence of NS3 RASs was higher in people exposed to an NS3 inhibitor (35% vs. 3.9%; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text